4-28-06

Attorney Docket No. 55600-8014.US01

IFW

PATENT

Express Mail Label <u>EV 337 220 060 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF:

Liu, et al.

APR 2 6 2006

APPLICATION NO.: 10/825,382

FILED: April 14, 2004

FOR: METHOD OF TREATMENT USING

INTERFERON-TAU

EXAMINER: Unassigned

ART UNIT: 1648

CONF. NO: 8686

Supplemental Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. <u>Cited Information</u>

Copies of references numbered 35, 41-42, 50 and 55 can be found in parent U.S. Application No. 10/824,710. References numbered 33, 36, 39, 47-48, and 56 can be found in U.S. parent Application No. 10/884,741. References numbered 32, 34, 37-38, 40, 43-44, 46, 49, 51, 54, 57 and 58 can be found in U.S. parent Application No. 11/112,369. References numbered 45 and 52 were cited by the examiner in U.S. parent Application No. 10/824,710.

3. <u>Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))</u>

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5.	<u>Paten</u>	t Term Adjustment (37 C.F.R. § 1.704(d))
		The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).
		Respectfully submitted, Perkins Coie LLP
Date:	4/3	July M. Mohr
		Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

BY060620.097 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

1

APR 2 6 2006

Form PTO-1449 (Modified)
(Use several sheets if necessary)

of

COMPLETE IF KNOWN					
Application Number	10/825,382				
Confirmation Number	8686				
Filing Date	April 14, 2004				
First Named Inventor	Chih-Ping Liu				
Group Art Unit	1648				
Examiner Name	Unassigned				
Attorney Docket No.	55600-8014.US01				

	· - · · · ·			U.S. PATENT DOCUMENTS		
Examiner Initials*	Cite No.		ation nd Code f known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages o Relevant Figures Appear
	1	H22		Creasey, et al.	02/04/86	
	2	4,683,195		Mullis, et al.	07/28/87	
	3	4,683,202		Mullis	07/28/87	
	4	4,752,479		Briggs, <i>et al</i> .	06/21/88	
	5	4,766,068		Oeda, et al.	08/23/88	
	6	4,769,235		Schlesinger, et al.	09/06/88	
	7	4,822,605		Powell	04/18/89	
	8	5,098,702		Zimmerman, et al.	03/24/92	
	9	5,128,126		Boniver	07/07/92	
	10	5,368,854		Rennick	11/29/94	
	11	5,376,368		Ulich	12/27/94	
	12	5,425,940		Zimmerman, <i>et al.</i>	06/20/95	
	13	5,563,126		Allen, <i>et al.</i>	10/08/96	
-	14	5,632,983		Hadden	05/27/97	
	15	5,880,114		Deluca, <i>et al.</i>	03/09/99	
	16	5,942,223		Bazer, et al.	08/24/99	
	17	6,080,742		Germann, et al.	06/27/00	
	18	6,346,243	B1	Brod	02/12/02	
	19	2003/0017136	A1	Cruz, et al.	01/23/03	
-	20	2003/0055013	A1	Brass	03/20/03	
	21	2003/0086901	A1	Cruz, et al.	05/08/03	
	22	6,613,354	B2	Depui, <i>et al.</i>	09/02/03	
	23	2003/0185799	A1	Rudolph	10/02/03	
	24	2003/0229044	A1	Steinman, et al.	12/11/03	
	25	2003/0232033	A1	Cantrell	12/18/03	
	26	2004/0009896	A1	Glynn, <i>et al.</i>	01/15/04	

3

EXAMINER		DATE CONSIDERED
*EXAMINER: Initia	al if reference considered, whether or not criteria is in conforman	ance with MPEP 609. Draw line through citation if not in conformance and not
consi	idered. Include copy of this form with next communication to a	application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

2

Sheet

	COMPLETE IF KNOWN					
Application Number		10/825,382				
Confirmation Number		8686				
Filing Date		April 14, 2004				
First Named Inventor		Chih-Ping Liu				
Group Art Unit		1648	·			
Examiner Name		Unassigned				
Attorney Docket	No.	55600-8014.US01				

U.S. Patent or Application Name of Patentee or Inventor of Cited Document Pages, Columns, Lines of Cited Document Name of Patentee or Inventor Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant Name of Cited Document Nam						U.S. PATENT DOCUMENTS				
28 6,699,496			Э	Kin	d Code		Publication or Filing Date of Cited	Where Relevant Passage	sor	
29 2004/086508 A1 Skurkovich, et al. 05/06/04		27	200	4/0013695	A1	Vande-Velde	01/22/04			
30 2005/0014734 A1 Chang 01/20/05 31 6,942,854 B2 Soos, et al. 09/13/05		28	6	,699,496	B1	Kojima, <i>et al</i> .	03/02/04			
Sample S		29	200	2004/0086508		Skurkovich, et al.	05/06/04			
FOREIGN PATENT DOCUMENTS Foreign Patent or Application Patent or Applicat		30	200	5/0014734	A1	Chang	01/20/05			
Examiner Initials Cite NUMBER Kind Code Name of Patentee or Applicant of Cited Document Passages or Relevant Passages or R		31	6	,942,854	B2	Soos, et al.	09/13/05			
Examiner Initials Pages, Columns, Lines,					FC	REIGN PATENT DOCUMENTS				
Stammer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. 34				• • •	Kind Cod	~ <u> </u>	Publication or Filing Date of Cited	Where Relevant Passages or Relevant	Т	
DTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. 34 Asadullah, K., et al., Pharmacological Reviews 55(2):241-269, (2003). 35 Chaouat, G., et al., J Immunology 154(9):4261-4268, (1995). 36 Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). 37 Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003). 38 Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995). 39 Groetzner, J., et al., Transplantation 77(4):568-574, (2004). 40 Jacobs, R., et al., Rheumatology 40:868-875, (2001). 41 Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).		32	EP	0 814 831	B1	Soos, et al.	06/19/02			
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. 34 Asadullah, K., et al., Pharmacological Reviews 55(2):241-269, (2003). 35 Chaouat, G., et al., J Immunology 154(9):4261-4268, (1995). 36 Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). 37 Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003). 38 Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995). 39 Groetzner, J., et al., Transplantation 77(4):568-574, (2004). 40 Jacobs, R., et al., Rheumatology 40:868-875, (2001). Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).		33	EP	1 241 242	A2	Paeschke, et al.	09/18/02			
Examiner Initials* Cite No. Asadullah, K., et al., Pharmacological Reviews 55(2):241-269, (2003). Chaouat, G., et al., J Immunology 154(9):4261-4268, (1995). Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003). Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995). Groetzner, J., et al., Transplantation 77(4):568-574, (2004). Jacobs, R., et al., Rheumatology 40:868-875, (2001). Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).										
35 Chaouat, G., et al., J Immunology 154(9):4261-4268, (1995). 36 Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). 37 Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003). 38 Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995). 39 Groetzner, J., et al., Transplantation 77(4):568-574, (2004). 40 Jacobs, R., et al., Rheumatology 40:868-875, (2001). 41 Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).		1				ial, symposium, catalog, etc.), date, page(s),			т	
36 Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). 37 Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003). 38 Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995). 39 Groetzner, J., et al., Transplantation 77(4):568-574, (2004). 40 Jacobs, R., et al., Rheumatology 40:868-875, (2001). 41 Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).		34	Asadı	Asadullah, K., et al., Pharmacological Reviews 55(2):241-269, (2003).						
37 Fainardi, E., <i>et al., J of Neuroimmunology</i> 142:149-158, (2003). 38 Goldman, M. and Velu, T., <i>Advances in Nephrology</i> 24:79-90, (1995). 39 Groetzner, J., <i>et al., Transplantation</i> 77(4):568-574, (2004). 40 Jacobs, R., <i>et al., Rheumatology</i> 40:868-875, (2001). 41 Kappos, L., <i>et al., J Neurol</i> , 251(Suppl 5):V/57-V/64, (2004).		35	Chaoi	uat, G., <i>et al.,</i>	J Imm	unology <u>154(</u> 9):4261-4268, (19	95).			
38 Goldman, M. and Velu, T., <i>Advances in Nephrology</i> <u>24</u> :79-90, (1995). 39 Groetzner, J., <i>et al., Transplantation</i> <u>77(4):568-574, (2004).</u> 40 Jacobs, R., <i>et al., Rheumatology</i> <u>40</u> :868-875, (2001). 41 Kappos, L., <i>et al., J Neurol</i> , <u>251(Suppl 5):V/57-V/64, (2004).</u>		36	Elices	, M.J., <i>Currer</i>	nt Opini	on in Investigational Drugs <u>4</u> (11):1354-1362,	(2003).		
39 Groetzner, J., et al., Transplantation 77(4):568-574, (2004). 40 Jacobs, R., et al., Rheumatology 40:868-875, (2001). 41 Kappos, L., et al., J Neurol, 251(Suppl 5):V/57-V/64, (2004).		37	Faina	rdi, E., <i>et al.,</i>	J of Ne	uroimmunology <u>142</u> :149-158, (2	2003).			
40 Jacobs, R., <i>et al., Rheumatology</i> <u>40</u> :868-875, (2001). 41 Kappos, L., <i>et al., J Neurol</i> , <u>251</u> (Suppl 5):V/57-V/64, (2004).		38 Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995).								
41 Kappos, L., <i>et al., J Neurol</i> , <u>251</u> (Suppl 5):V/57-V/64, (2004).	40 Jacobs, R., et al., Rheumatology <u>40</u> :868-875, (2001).									
42 Killestein, J. and Polman, C.H., <i>Curr Opin Neurol</i> , 18:253-260, (2005).					4).		-			
,		42	Killest	ein, J. and Po	olman,	C.H., <i>Curr Opin Neurol</i> , <u>18</u> :253-	·260, (2005).			

DATE CONSIDERED

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to application(s).

*EXAMINER: BY060620.065

EXAMINER

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

. ,

Sheet

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

COMPLETE IF KNOWN					
Application Number	10/825,382				
Confirmation Number	8686				
Filing Date	April 14, 2004				
First Named Inventor	Chih-Ping Liu				
Group Art Unit	1648				
Examiner Name	Unassigned				
Attorney Docket No.	55600-8014.US01				

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	43	Kozlowski, L., et al., Annales Acedemiae Medicae Bialostocensis 48:82-84, (2003).	
	44	Leon, L.R., et al., Annals of the New York Academy of Sciences 856:69-75, (1998).	
	45	Li, et al., World Journal of Gastroenterology 10:620-625, (2004).	
	46	Macdougall, I.C. and Cooper, A.C., Nephrol Dial Transplant 17(Supp 11):39-43, (2002).	
	47	Martin, J., et al., Cytokine 10(8):635-644, (1998).	
	48	Miller, D.H., et al., N Engl J Med 348:15-23, (2003).	
	49	Murray, H.W., et al., Infection and Immunity 70(11):6284-6293, (2002).	
	50	Olek, M.J., <i>et al., Neurology</i> <u>56</u> (Suppl 3):A76, (2001).	
	51	Rennick, D.M. and Fort, M.M., Am J Physiol Gastrointest Liver Physiol 278:G829-G833, (2000).	
	52	van Roon, et al., Journal of Rheumatology 30:648-651, abstract only.	
	53	Sandborn, W.J. and Yednock, T.A., <i>American Journal of Gastroenterology</i> 98(11):2372-2382, (2003).	
	54	Soltys, J., et al., J of Immunol 168:1903-1910, (2002).	
	55	Tuo, W., et al., J Interferon and Cytokine Research 19(2):179-187, (1999).	
-	56	Vanderhoff, B.T., and Tahboub, R.M., Am Fam Physician 66:273-280, (2002).	
	57	Wang, B., et al., J Immunol <u>162</u> :277-283, (1999).	
	58	Waubant, E., et al., J of Neuroimmunology <u>112</u> :139-145, (2001).	

3

		D. ATT. CO.VOIDEDED			
EXAMINER		DATE CONSIDERED			
*EXAMINER:	: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
	considered. Include copy of this form with next communication to application(s).				